Initial manufacturing for Pfizer's clinical trial for the COVID-19 vaccine will take place in Kalamazoo, Governor Gretchen Whitmer said.
The first participants have been dosed in the trial.
“This is great news for our families, our neighbors, and those serving on the front lines during this crisis,” said Governor Whitmer. “COVID-19 has shown how vulnerable our country is when it comes to supply chain and much of the lifesaving materials we need are manufactured out of the country. That’s why we are so proud that one of the largest pharmaceutical manufacturing facilities in the world is the Pfizer site right here in Kalamazoo, Michigan. In fact, Michigan has a strong history of vaccine development with the polio and anthrax vaccines. Pfizer is a great partner and the State of Michigan and our strong manufacturing roots stand ready to serve.”
The company's clinical trial supply will be made at sites in Andover, Massachusetts and Chesterfield, Missouri.
The trial is part of a global development program.
The first stage of the study is taking place at four sites across the U.S. – NYU School of Medicine; University of Maryland School of Medicine; University of Rochester School of Medicine; and Cincinnati Children’s Hospital, with plans to rapidly scale up the number of sites across the country
Additional Coronavirus information and resources:
Click here for a page with resources including a COVID-19 overview from the CDC, details on cases in Michigan, a timeline of Governor Gretchen Whitmer's orders since the outbreak, coronavirus' impact on Southeast Michigan, and links to more information from the Michigan Department of Health and Human Services, the CDC and the WHO.
View a global coronavirus tracker with data from Johns Hopkins University.
Find out how you can help businesses and restaurants struggling during the pandemic.
Also, get information about Rebound Mid Michigan, with stories, information and more about coming back from COVID-19
Join the Rebound Mid Michigan Facebook Group.
See complete coverage on our Coronavirus Continuing Coverage page.